+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Recent advances in rilpivirine: new data and promising treatment option



Recent advances in rilpivirine: new data and promising treatment option



Aids Reviews 16(3): 172-181



The usefulness of every antiretroviral drug in the clinical setting should be continuously evaluated, since registration studies may not adequately reflect real-world patient populations. Rilpivirine was developed in an effort to generate patient-tailored drugs with high convenience and minimal side effects. By now, rilpivirine is currently licensed for use with other antiretroviral agents, and as a single agent or a single-tablet regimen with tenofovir and emtricitabine , in antiretroviral-naive, HIV-1-infected adults with < 100,000 HIV-1 RNA copies/ml because of a higher rate of virological failure above this level. However, after its introduction several questions remained to be elucidated, such as the efficacy of rilpivirine with abacavir/lamivudine, or its use in switching strategies, a useful alternative for patients with toxicity or intolerance. Cumulative data suggest the efficacy and safety of the combination of abacavir/lamivudine plus rilpivirine in the clinical setting, and an increasing number of patients received rilpivirine after protease inhibitor, efavirenz, or nevirapine-based therapy without compromising rilpivirine exposure after the change. Moreover, rilpivirine is a substrate and weak inducer of the CYP3A4, but there are no significant pharmacokinetic interactions with new anti-hepatitis C compounds such as telaprevir, simeprevir, daclatasvir, ledipasvir, and sofosbuvir, an important issue for a drug with low risk of hepatoxicity. As a new and promising strategy, rilpivirine has been evaluated with darunavir and dolutegravir in dual therapies, without need of dose adjustment and with adequate preliminary data. Therefore, to date, new data on rilpivirine confirm the good results observed in the clinical trials.

(PDF emailed within 1 workday: $29.90)

Accession: 055398577

Download citation: RISBibTeXText

PMID: 25221991


Related references

Dolutegravir Plus Rilpivirine as a Switch Option in cART-Experienced Patients: 96-Week Data. Annals of PharmacoTherapy: 1060028018761600-1060028018761600, 2018

Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances. Therapeutic Advances in Vaccines 2(5): 137-148, 2014

Recent advances on natriuretic peptide system: new promising therapeutic targets for the treatment of heart failure. Pharmacological Research 76: 190-198, 2014

Recent advances in cochlear hair cell regeneration-A promising opportunity for the treatment of age-related hearing loss. Ageing Research Reviews 36: 149-155, 2017

New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir. Hiv/Aids 4: 61-71, 2012

Diagnosis and treatment of cardiovascular diseases.Recent advances.Recent advances in the treatment of hypertension. Nihon Naika Gakkai Zasshi 84(3): 342-346, 1995

Immunotherapy in Melanoma: Recent Advances and Promising New Therapies. Journal of Pharmacy Practice 28(2): 193-203, 2014

Iminosugars as therapeutic agents: recent advances and promising trends. Future Medicinal Chemistry 3(12): 1513-1521, 2011

TGF- as Promising Option in Treatment of Multiple Sclerosis. 2009

Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation. Mediators of Inflammation 2017: 9673537-9673537, 2017

Recent advances in liposomal nanohybrid cerasomes as promising drug nanocarriers. Advances in Colloid and Interface Science 207: 32-42, 2015

Bone tissue engineering: recent advances and promising therapeutic agents. Expert Opinion on Biological Therapy 3(3): 409-423, 2003

Therapeutic potential of KCa3.1 blockers: recent advances and promising trends. Expert Review of Clinical Pharmacology 3(3): 385-396, 2010

Isoform-specific inhibitors of ACATs: recent advances and promising developments. Future Medicinal Chemistry 3(16): 2039-2061, 2012

Medical treatment with misoprostol for early failure of pregnancies after assisted reproductive technology: a promising treatment option. Fertility and Sterility 91(5): 1881-1885, 2008